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ENGLISH SUMMARY 
Chronic obstructive pulmonary disease is a major public health issue that influences 
mortality, quality of life and the expenditure of health resources. As yet, we can only 
imperfectly predict the individual clinical course. This thesis, consisting of three 
observational, register-based cohort studies explores integrative risk factors in acute 
exacerbations of COPD and traces changes in the clinical management of 
exacerbations in Denmark over time.  
Study I, which explored previous exacerbations as a risk factor, included 6,656 
patients treated with assisted ventilation for exacerbation of COPD. Of these 44% died 
in-hospital. Patients with previous exacerbations had higher mortality both in-hospital 
and after discharge. The larger the number of previous admissions, the higher 
mortality.  
Study II, in which changes in the use of assisted ventilation in COPD and mortality 
were traced, included 173,456 patients. Compared to 2004, a much higher number of 
patients were treated with assisted ventilation in 2011, and non-invasive ventilation 
gradually became the dominant mode, while the absolute number of invasive 
ventilations was stable. In spite of the increase in the number of treatments, mortality 
was relatively unchanged.  
Study III, which explored the association between mortality after an exacerbation and 
haemoglobin at admission, included 6,969 patients. Mortality with anaemia in-
hospital was about twice as high as mortality among patients with normal 
haemoglobin. After discharge, mortality increased the more haemoglobin deviated 
from normal values. 
In conclusion, this dissertation shows that both previous exacerbations and 
haemoglobin at admission are risk factors for mortality among COPD patients, and 
that the introduction of non-invasive ventilation has evoked a profound change in the 
treatment of severe exacerbations where more patients are treated with assisted 
ventilation.
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DANSK RESUME 
Kronisk obstruktiv lungesygdom (KOL) er et betydeligt folkesundhedsmæssigt 
problem med følger for både dødelighed, livskvalitet of sundhedsudgifter. På 
nuværende tidspunkt kan vi kun ufuldstændigt forudsige forløbet for den enkelte 
KOL-patient.  Denne afhandling, som består af tre observationelle, registerbaserede 
kohortestudier undersøger integrative risikofaktorer in forbindelse med akutte 
forværringer og undersøger ændringer i den kliniske håndtering af disse forværringer 
i Danmark over tid. 
Det første studie, som undersøgte tidligere indlæggelser som risikofaktor, inkluderede 
6.656 patienter behandlet for alvorlig KOL-forværring med assisteret ventilation. Af 
disse døde 44% under indlæggelsen. Patienter med tidligere forværringer havde højere 
dødelighed både under indlæggelse og efter udskrivelse. Jo flere tidligere AECOPD 
indlæggelser en patient havde haft, jo større dødelighed.   
Det andet studie, som undersøgte ændringer i brugen af assisteret ventilation under 
KOL-forværringer og den samtidige mortalitet, inkluderede 173,456 patienter. I 
forhold til 2004 fik langt flere patienter behandling med vejrtrækningsstøtte i 2011 og 
non-invasiv ventilation blev efterhånden den dominerende ventilationsform mens det 
årlige absolutte antal behandlinger med invasiv ventilation var stabilt. Til trods for 
stigningen i antallet af behandlinger ændredes dødeligheden i forbindelse med 
ventilation sig stort set ikke.  
Det tredje studie, som undersøgte sammenhængen mellem dødelighed i forbindelse 
med KOL-forværringer og hæmoglobinværdien ved indlæggelse, inkluderede 6,969 
patienter. Dødeligheden blandt patienter der præsenterede sig med anæmi var dobbelt 
så høj under indlæggelsen. Efter udskrivelse steg dødeligheden jo længere 
hæmoglobinværdien var fra normalområdet.  
Samlet viser denne afhandling, at både tidligere indlæggelser og hæmoglobinværdier 
er risikofaktorer for død blandt KOL patienter, og at måden man behandler akutte 
forværringer af KOL har ændret sig grundlæggende, således at man i dag behandler 
langt flere patienter med vejrtrækningsstøtte. 
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INTRODUCTION 
The present thesis focuses on exacerbation of Chronic Obstructive Lung Disease, their 
treatment and risk factors for mortality. 
1.1. CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD) 
According to the present recommendations from the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), COPD is   
“a common preventable and treatable disease, … characterized by persistent 
airflow limitation that is usually progressive and associated with an enhanced 
chronic inflammatory response in the airways and the lung to noxious particles or 
gases….” 1 
It is also an extremely diverse and complex disease, the progression of which no 
intervention has proven efficient in halting1. Emphysema, bronchitis and 
bronchiolitis, the pulmonary hallmarks of COPD, have been recognised for centuries, 
but the different manifestations were not conceptually unified till the second part of 
the Twentieth Century 2, and the systemic nature of the disease just begins to unravel. 
Of large importance in COPD are acute exacerbations, AECOPDs, which are  
“acute events characterized by a worsening of the patient’s respiratory symptoms 
that is beyond normal day-to-day variation and leads to change of medication” 1 
The term exacerbation covers a wide range of clinical presentations, from an 
aggravation of symptoms manageable in the primary sector to life-threatening acute 
respiratory insufficiency. Severity of exacerbations can be graded according to the 
Antonisen criteria 3. 
With decreasing severity: 
Type 1: Increased dyspnoea AND increased sputum volume AND increased sputum 
purulence 
Type 2: Two of the Type 1 criteria 
Type 3: One of the Type 1 criteria AND at least one of the following: upper respiratory 
infection within the last 5 days, fever without other cause, increased wheezing, 
increased cough, an increase in respiratory rate or heart rate by at least 20%.  
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1.1.1. FORMAL DEFINITION OF COPD 
Clinically, the severity of the airflow limitation can be assessed with spirometry in 
stable phase. For the GOLD diagnosis of COPD to be made, the ratio of forced 
expiratory volume in one second (FEV1) to forced vital capacity (FVC) must fail to 
reach 0.7 after administration of a bronchodilating agent. Mild, moderate, severe, and 
very severe COPD are characterized by FEV1 of more than 80%, less than 80%, less 
than 50%, and less than 30%, predicted for age, height, sex and race 1. The GOLD 
definition has been critisised for underdiagnosing COPD in certain subgroups 4,5.  
1.1.2. BRIEF OVERVIEW OF THE PATHOLOGY AND PHYSIOLOGY IN 
COPD 
The pathological development of COPD involves inappropriate inflammation, 
usually, but not always, provoked by inhaled irritants (tobacco or air pollution)6–8. 
COPD is a disease with conspicuous pulmonary symptoms, but the disease also has a 
systemic impact with discernible pathological changes in multiple tissues and organ 
systems.  
The relative importance of different pathological processes in the lungs shows inter-
individual variation, but emphysema (destruction of the parenchymal tissue), 
bronchitis/bronchiolitis (inflammation and hypersecretion in the airways) are central 
processes 9.  
Patophysiologically, the consequence of emphysema and bronchitis are 10–12:  
 Expiratory flow limitation 
The resistance to exhalation increases due to diminished elastic recoil, which 
leads to dynamic airway collapse, and to inflammation, swelling, and mucus 
secretion in the airways. 
 Static hyperinflation of the lungs, by which patients with COPD can to some 
extent adapt to and compensate for the increased airflow resistance  
 Increased mismatch of ventilation and perfusion, which leads to increasing 
dead-space ventilation and impaired diffusion of oxygen. 
 Increased work of breathing, which arises from the increased ventilation, the 
hyperinflation and the increased airway resistance. 
The pathological changes in the lungs are compensated by biochemical compensation. 
The renal excretion of CO2 increases as does the concentration of CO2 in exhaled air, 
0.  
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but the CO2 level in the blood is reset at a higher level. In stable phases of COPD, this 
accumulation of CO2 is counterbalanced and the pH remains normal 13. 
Inflammation in the lungs is a cornerstone in the progression of COPD 14 but evidence 
of inflammatory processes is also present in extrapulmonary tissues. The overarching 
concept of “systemic inflammation”, which is the preferred term in the literature, has 
been adopted although it has neither been rigorously defined nor conceptually 
disentangled from comorbidities 15. Evidence suggests that the balance between pro- 
and anti-inflammatory processes is shifted towards a state of sustained inflammation 
in COPD. The effects of this shift are profound and can be measured as altered 
regulation of inflammatory mediators and functionally in changes in metabolism 16,17. 
Multiple biomarkers have been employed as indicators of systemic inflammation in 
COPD, among others white blood cell count/neutrophils, CRP, IL-6, IL-8, fibrinogen, 
procalcitonin, erythropoietin and TNF-α, but associations are not straight-forward as 
inflammatory markers are neither present in stable concentrations over time 18 nor 
specific for COPD. In spite of this, inflammatory markers do predict future 
exacerbations 19, accelerated lung function decline 20,  and mortality21. 
Profound damage can be observed in organs other than the lungs and and a wide 
spectrum of diseases are seen among COPD patients more frequently than among age-
matched controls 22 . This is hardly surprising as the main risk factor for COPD, 
tobacco, influences virtually every organ system and other life style risk factors cluster 
with smoking 23. Furthermore, the association between COPD and certain 
comorbidities seems to be stronger than shared risk factors can explain, pointing to a 
biological interplay 24. Mechanically, the heart is affected (the cardiopulmonary 
coupling) 25, and inflammation spills over to or is initiated in other organ systems 
17,24,26.  
During acute exacerbations, the lungs and airways exhibit further pathological 
changes often brought about by viral or bacterial infections 27. There is a clinical 
overlap between non-pneumonic exacerbations of COPD and pneumonia, but the 
clinical courses of exacerbations with pneumonia or indeed just with a consolidation 
on chest x-ray are more severe 28,29. 
The major changes in the lungs during a COPD exacerbation are increased airway 
wall inflammation with oedema, bronchoconstriction, and hypersecretion. In 
combination, these changes lead to aggravated expiratory flow limitation and dynamic 
hyperinflation 27.  This again leads to a increased work of breathing. To sustain the 
alveolar ventilation necessary for adequate gas exchange, the respiratory rate 
increases and the muscles normally involved in respiration are aided by the auxillary 
respiratory muscles. 
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In about 21 % of hospitalised COPD exacerbations these compensatory mechanisms 
are inadequate 30 and alveolar ventilation cannot be sustained. The hypoventilation 
results in respiratory (hypercapnic) acidosis often associated with hypoxia and/or 
metabolic acid-base disturbances, directly caused by hypoxemia or by concomitant  
comorbidities 13. Even though the inherent compensatory mechanisms can to some 
extent prevent a deleterious acidosis 13 , a vicious circle is initiated, which will develop 
fatally if the work of breathing is not reduced 31. 
1.1.3. EPIDEMIOLOGY 
COPD  is a major causes of mortality and morbidity worldwide, where COPD is 
projected to be the fourth leading cause of death by 2030 32. It has a severe impact on 
patient quality of life 33 and utilisation of health care resources 34,35. In Denmark, 
surveys suggest that about 420,000 citizens fulfill the criteria for COPD 36 and that 
COPD is stated as the direct cause of about 3,500 deaths per year 37.  
COPD is generally known to be underdiagnosed 38 and underreported as the cause of 
death 39. Even in the Nordic countries, with comprehensive primary health care 
systems, the prevalence of undiagnosed COPD is high 40 and formal diagnoses, i.e. 
those that are spirometrically verified, have only been made in a minority of the 
patients medicated for COPD 41.  
AECOPDs can intercept the progression of COPD at any stage, though they are more 
frequent in advanced COPD 42–44.  The risk of death is increased during the 
exacerbation 45,46 and the impact on the further clinical course of survivors is negative 
with enhanced disease progression 46, diminished quality of life 46,47, enhanced risk of 
recurrent exacerbations, and increased long-term mortality 43,46. 
COPD patients in GOLD stages 2, 3, and 4 experience on average 0.85, 1.34 and 2.00 
AECOPDs respectively per year, but only 0.11, 0.25, and 0.54 exacerbations anually 
lead to hospitalisation 42. AECOPDs are a common cause of death among COPD 
patients and in particular among patients with advanced COPD 48. The overall short-
term mortality of exacerbations ranges from 2.1% to 20.4% 35,45,49,50 but patients with 
severe acute COPD admitted to intensive care are particularly at risk with a six-month-
mortality ranging from 25%-40% 49,51,52.  Populations are not directly comparable as 
the level of care needs that dictates a referral to an ICU may depend on the 
organisation and level of competence in the medical wards.    
Although exacerbations are in general more frequent in severe COPD, recent evidence 
points to the fact that the occurrence of exacerbations varies extensively among COPD 
patients with similar lung function in stable periods and that exacerbations are the best 
predictor of their own recurrence 42,53. It has been suggested that an inherent “frequent-
0.  
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exacerbation phenotype” with a distinct pathophysiology 42,54 might explain at least 
part of the extensive variability in clinical courses.  
1.1.4. TREATMENT OF EXACERBATIONS 
1.1.4.1 Medical treatment 
The first line of treatment of AECOPD is intensified medical treatment with inhaled 
bronchodilators, systemic glucocorticoids, and antibiotics and, in hospital, 
supplemental oxygen 1. This treatment, however, might be insufficient or started too 
late. In this case, the compensatory mechanisms become overtaxed and fail to ensure 
sufficient ventilation, the failure of which leads to respiratory acidosis 55,56. If patients 
deteriorate even though optimal medical therapy and supplementary oxygen are 
administered, assisted ventilation is the second line of treatment 1.  
1.1.4.2 Assisted ventilation 
Mechanism 
The vicious circle of insufficient gas exchange can be broken by assisted ventilation. 
This treatment buys time for the medical treatment to take effect and works by 
counteracting the deleteriously increased work load imposed by diminished elastic 
recoil and increased airway resistance.  
Assisted ventilation in AECOPD can be administered either invasively or non-
invasively. Invasive ventilation (IMV) is administered via an endotracheal tube in the 
most severe cases of AECOPD, and always under continuous surveillance in an 
intensive care unit (ICU).  
NIV is the technical term for a range of non-invasive treatment modalities. Including, 
among others, CPAP and BiPAP. NIV always supports the patient’s own ventilation, 
which means that deep sedation is not necessary and that the patient can communicate 
and have breaks. The support can be given by the application of continuous positive 
airway pressure (CPAP) or variable pressures timed with the patient’s own pattern of 
ventilation (BiPAP) 57. It should be noted that the NIV notation is ambiguous and that 
CPAP is not always included in the “non-invasive ventilation term” 57. In the present 
guidelines, CPAP is not recommended for AECOPD in Denmark 58 and will therefore 
not be further considered here. Throughout this thesis, NIV is used synonymously 
with BiPAP. 
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Whereas solid evidence, derived from trials and to some extent from observational 
studies, supports the superiority of NIV compared to standard medical care in 
AECOPD 59, few studies have compared NIV to IMV. The sole randomised controlled 
trial found that the two treatments were associated with equal short-term mortality 
rates but a trend towards increased 1-year survival in the NIV group 60. In 
observational studies, NIV has been advantageous compared to IMV 61–63, but as the 
studies are observational, causality cannot be directly inferred.   
NIV 
NIV has been implemented as therapy of choice for hypercapnic respiratory failure in 
AECOPD. At present, Danish guidelines recommend initiation of NIV in COPD 
exacerbations if pH≤7.35 and partial arterial pressure of CO2 (PaCO2) ≥ 6.0 in the 
absence of respiratory arrest and misfitting masks (absolute) and impaired 
conciousness, copious secretiong, cardiovascular impairment, danger of vomiting, 
and  claustrophobia. NIV is recommended even in spite of relative contraindications, 
if advancement orders proscribe intubation 64. However, NIV seems to be used 
extensively in both patients with relative contraindications to NIV and in patients 
without a formal indication for NIV 65. Studies continuously explore new indications 
to NIV and challenge the present contraindications 66,67. Other surveys have, however, 
found high failure rates upon “off-indication” NIV treatment 68.     
A successful outcome of NIV treatment is known to correlate with lower age and rapid 
reduction of acidosis upon NIV-initiation 69. NIV failure is likewise associated with 
older age, low Glasgow Coma Score, severe acidosis and tachypnoea, mixed acid-
base disorders, slow or lacking normalisation of pH in addition to poor NIV tolerance 
and poor adherence to therapy 30,70–73. Notably, the relation between late failure, i.e. 
later than 48 hours post NIV-initiation, and immediate improvements in gas exchange 
seems to be weak 71. Few studies have examined the association between the previous 
clinical history of the patient and the outcome of NIV, although the additional risk 
attributable to being old and male is known 74. 
IMV 
IMV remains a necessary back-up modality in case NIV is not available, in case of 
primary contraindications of NIV, and in case of insufficient effect of an initial NIV 
trial (NIV failure). An initial trial of NIV is often warranted prior to initiation of IMV, 
but patients with manifest, impending or threatening respiratory or cardiac arrest, i.e. 
patients with loss of conciousness, haemodynamic instability and apnoea, the airways 
should be immediately secured by insertion of a endotracheal tube 1.  
Prognostic factors following ICU admission for COPD are numerous but few studies 
have focused solely on patients treated with invasive ventilation and most studies also 
0.  
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include patients admitted to ICU for COPD without ventilation. The in-hospital 
mortality for COPD patients admitted to ICU is associated with age, sex, 
comorbidities, cardiopulmonary resuscitation (CPR), resuscitation prior to ICU 
admission, PaCO2 and acidosis, organ failure and acute severity scoring systems 75–77. 
Mortality in the first 6 months after ICU admission is associated with low Glasgow 
Coma Scale scores, CPR arrest prior to ICU admission, cardiac dysrhythmia, length 
of hospital stay, and higher values of acute physiology scoring systems 52,78. Among 
patients treated with IMV, low haemoglobin has been shown to predict 3 months 
mortality 79. Age and hospital length of stay have been shown to associate with 1-year 
mortality after ICU admission 51. Comorbidity has been inconsistently associated with 
mortality 80,81 but conclusions should be drawn with caution as (collider) bias might 
have been introduced by the selection of patients for ICU and IMV. 
In a large European audit, only 51 % and 15 % of patients meeting the criteria for NIV 
and IMV respectively, had these treatments 82. This underuse might be partly due to 
limits of care agreed upon by clinicians and patients at a previous consultation 83, but 
even among patients without such limitations, assisted ventilation appears to not 
always be instigated 84. Possible explanations for this discrepancy are multiple, and 
probably, though literature in this field is scarce, include overt futility and refusals 
given by patients on the spot.  
Among arguments against or barriers to initiation of assisted ventilation are: 
 The chronic and progressive nature of the disease. 
Pessimism on behalf of COPD patients is widespread among clinicians and high 
mortality rates both during treatment and after discharge are expected 85. In-hospital 
mortality rates among patients treated with assisted ventilation for AECOPD are in 
the range of 5 % - 25 % 30,61,62,86,87. Though an inference of mortality as it would have 
been if all AECOPD patients with uncompensated ARF were treated with assisted 
ventilation per se cannot be  drawn, arguably it would have been higher. Surveys have, 
however, demonstrated that the prevalent clinical pessimism is somewhat exaggerated 
especially concerning COPD patients with advanced disease 88. In addition, even 
among inevitably dying patients, assisted ventilation, in that case NIV, might be 
justified for palliative purposes 89  
 Fear of adverse events 
Reports on the frequency of complications of ventilation in COPD patients are scarce. 
The major complications of ventilation are pneumonia, barotrauma, and 
haemodynamic alterations. Non-invasive ventilation results in fewer complications 90, 
but 8 - 30 % of NIV patients experience failure in trials 91 and in observational surveys, 
COPD EXACERBATIONS – ASSISTED VENTILATION, HAEMOGLOBIN AND PROGNOSIS 
20 
5 - 24 % of patients initially treated with non-invasive ventilation have their treatment 
escalated to invasive ventilation 86,92,93.    
 Shortage of capacity 
Treatment with invasive ventilation is in general only feasible in ICUs, whereas non-
invasive ventilation can be administered in respiratory or otherwise specialised 
medical wards, however it requires a high nurse-to-patient ratio. That capacity has an 
impact on the decision to admit a patient to ICUs has been documented but the impact 
on mortality of restrictions due to bed shortage is not clear 94–98.  
1.1.4.3 Choice of mode of assisted ventilation in AECOPD 
NIV has only recently been added to the armamentarium for the treatment of 
AECOPD. The first reports of benefit in AECOPD date back to the early 1980s and 
the seminal randomised controlled trials were conducted at the beginning of the 1990s 
99. Some countries, e.g. France and the USA, were swift to phase in this new treatment 
option, whereas it was not endorsed in Denmark until 2003.  
Many factors unrelated to the clinical condition of the patient are likely to influence 
the initial choice of mode of assisted ventilation in AECOPD. Among those, 
accessibility and capacity 100, case volume, tradition and habits 87,100,101, and the 
presence of specialised pulmonologists 102 have been documented.     
In addition, experience with the choice of ventilator mode continually broadens. Trials 
of NIV in populations where NIV was previously considered contraindicated have 
demonstrated that NIV is feasible in, for instance, patients with cerebral depression 
due to hypercapnia 67. On the other hand, other studies have demonstrated that NIV 
failure rates are high among patients with COPD patients with pneumonia 103, low 
Glasgow Coma Score, high respiratory rate and low pH 104 and have suggested that 
mortality is higher among patients initially treated with NIV and afterwards 
transitioned to IMV than among patients initially treated with IMV 86.  
Changes in the use of assisted ventilation in AECOPD over time was the focus of 
study II. 
1.1.5. PROGNOSIS 
The disease entity COPD covers a diverse range of clinical presentations, the 
prognosis of which differs markedly. Previously, bronchitis and emphysema were 
considered distinct disease entities105. Patients with dominant emphysema, clinically 
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presenting with unrelenting dyspnoea, loss of weight, and muscle wasting, were 
referred to as “pink puffers”. Patients with dominant chronic bronchitis, clinically 
often presenting with pulmonary hypertension and heart failure, were dubbed “blue 
bloaters”106. These stereotypes are, however, obsolete as they are imprecise and add 
little to either diagnosis or treatment 9. 
COPD patients are, nonetheless, grouped clinically, and different classification 
schemes have been designed with the aim of predicting morbidity as well as mortality 
and to qualify choices of treatment for individual patients. The present GOLD 
recommendations are that COPD patients are classified according to an A to D 
classification based on lung function impairment, symptoms, and previous 
exacerbations 1, but this classification has not been shown to supercede lung function 
per se in prediction of mortality 107. Other multidimensional indices (the BODE index 
- BMI, Obstruction, Dyspnoea, Exercise - or the BODE index in combination with the 
COTE index - comorbidities) have shown predictive values superior to the GOLD 
classification 108. That indices which integrate information on functional and 
metabolic parameters seem to improve prognostication supports the notion of COPD 
as “more than a disease of the lungs”. 
1.1.5.1 Methodological concerns pertaining to the study of prognosis in COPD 
Prior to a discussion of prognostic factors, the differences between prognostication in 
stable COPD patients and prognostication in COPD patients with ongoing 
exacerbation should be appreciated. These differences might to some extent explain 
why risk factors in stable phase and acute exacerbations only partly overlap. 
Study design: Studies of the prognosis of COPD patients with exacerbation are per se 
inception cohort studies. The inception is, broadly speaking, fixed to a certain point 
in time (day of hospitalisation, day of discharge etc.) which is determined primarily 
by the clinical course. In stable phase COPD the study cohort might not even be an 
inception cohort (patients might all be patients at a clinic or all citizens in a community 
with a recorded diagnosis of COPD at a given point in time) or the time of inception 
might to some extent reflect the perceived diagnosis (referral to a specialist clinic or 
the referral for domiciliary oxygen).  
Study population: Exacerbations in themselves are markers of severe disease and/or 
rapid disease progression109, and the inclusion of only patients with exacerbations 
therefore selects a high-risk sub-population in which relations between prognostic 
factors and outcome might differ from the relations in low risk populations.  
Misclassification: A considerable number of COPD patients have not been diagnosed 
with COPD prior to the first exacerbation 110–113 and therefore cannot have any 
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reasonably recent measurement of lung function. Comorbidities are underdiagnosed 
in COPD in general114 but arguably the rate of underdiagnosis may be different in 
these diagnosis-naïve patients. Prognostication during exacerbations will therefore to 
some extent have to rely on factors attainable in the acute phase.  
Finally, some prognostic factors might only exist or be revealed during an 
exacerbation. Infections, while they do play an important role in stable phase COPD, 
are life-threatening during exacerbations. Also, during an exacerbation the 
compensatory reserve is explored, as exacerbations constitute periods with staggered 
physiological equilibria.  
The following, not exhaustive, outline of risk factors will focus on mortality during 
or after exacerbations. 
1.1.5.2 The prognostic role of acute physiological derangement 
Hypoxia at admission to hospital is strongly associated with both short and long-term 
mortality 49. A wide range of other parameters, acidosis, hypercarbia, confusion, 
respiratory rate, and tachycardia, reflecting the severity of respiratory failure have 
likewise in different studies been associated with short-term mortality, but data are 
scarce on the association with long-term outcome.   
1.1.5.3 Stable phase severity of COPD and prognosis in exacerbations 
Lung function impairment (LFI), gauged in stable phase either as the measured FEV1 
relative to FEV1 as predicted from age, height, and ethnicity or as FEV1/FVC, is one 
of the most extensively studied prognostic factors during exacerbations as well as in 
stable phase COPD 115. Since the studies presented in this thesis are register-based no 
assessments of stable-phase LFI were accessible which is a limitation to the studies. 
Other relevant severity markers that would have limited confounding in the studies 
are subjective dyspnoea and use of domiciliary oxygen which both predict both long 
and short-term mortality49,116,117.   
1.1.5.4 Exacerbations 
It is well known that frequent exacerbations are associated with mortality in COPD 
118. The risk of death is high during an exacerbation and mortality remains elevated 
after lung function and burden of symptoms are restored to pre-exacerbation level 46. 
Causal inference should, however, be only cautiously drawn pertaining to 
exacerbations and long-term mortality. It might be that exacerbations, instead of being 
causal agents, are instead just markers of severe and rapidly progressing disease.   
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The association between previous exacerbations and mortality in patients ventilated 
for AECOPD was the focus of study I. 
1.1.5.5 Anaemia 
That pulmonary disease evokes changes in the blood and the circulatory system has 
been long established.  As early as 1913, F. Parkes Weber in “The Prognostic 
Significance of Secondary Polycythæmia in Cardio-pulmonary Cases” 119  presented 
patients with pulmonary failure and polycythaemia. The presence of polycythaemia 
was ascribed the to enhanced erythropoiesis in response to tissue hypoxia. Weber 
recognised the prognostic significance of polycythaemia: 
“With the "cardio-pulmonary cases,[…] the outlook is exceedingly grave at the 
stage of the disease when cyanosis and a great degree of polycytheemia become 
striking clinical features”, 
though he did not comment on the significance of anaemia. Interestingly, Weber 
stated that   
“…so far as I can judge, the best marked polycythaemic reactions occur in 
individuals (especially chronic asthmatics) of Jewish race, and at about middle age, 
when the reactive powers are stronger than in old age…”, 
which suggests that, in spite of the somewhat archaic reference to “reactive powers”, 
he appreciated the complexity of alterations to erythrocyte homeostasis in COPD. 
Formerly, polycythaemia, and not anaemia, was considered the most important 
erythrocyte-related disturbance in COPD. From a pathophysiological perspective, 
polycythaemia is the natural homeostatic  response to tissue hypoxia and especially 
before the introduction of domiciliary oxygen treatment, COPD was an important 
cause of secondary polycythaemia120. Nonetheless, compared to polycythaemia, 
anaemia has been shown to be far more frequent in modern day COPD populations. 
Dependent on the population, different types of anaemia predominate, but iron-
deficiency anaemia (IDA) and “anaemia of chronic disease” (ACD), and 
combinations thereof, are most frequently encountered 121. 
Iron deficiency anaemia results from depleted iron stores due to either insufficient 
intake of haemoglobin or excessive loss.  The relative importance of these 
mechanisms is highly dependent on the characteristics of the population but blood 
loss is a major factor in high-income countries 122. IDA is prevalent among COPD 
patients 123 and is associated with negative outcomes 121.    
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Concentrations of haemoglobin are in general lower in patients with systemic disease 
(diabetes, heart failure, kidney failure, cancer, chronic infection etc.)124 which has led 
to anaemia being considered an inflammatory marker. The mechanisms underlying  
ACD  are complex alterations in iron handling  and erythrocyte processing mediated  
by inflammatory mediators and result in:    
 the reduction in the lifespan of erythrocytes;  
 the impaired proliferation of erythroid progenitor cells;  
 the increased uptake and retention of iron within cells of the 
reticuloendothelial system (RES). 124.  
Multiple studies have addressed the presence and importance of different types of 
anaemia in COPD and have undertaken extensive biochemical characterisation 16. 
Given, however, that the relative frequencies of different types of anaemia have varied 
highly across populations 123,125, and that the only large studies of prevalence either 
were conducted in patients with LTOT 126 or in patients where anaemia was only 
recorded as a diagnostic code 127,  we still felt that a study of the mere presence of 
anaemia and polycythaemia in a large, non-selected cohort was justified and the 
association between concentrations of haemoglobin and mortality was the focus of 
study III.  
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AIMS OF THE THESIS 
The overall aim of the present thesis is to add to the understanding of the natural 
history of COPD and the implications of changing treatment approaches and to 
improve prognostication.  
1.1. HYPOTHESES 
On a general level, the hypotheses of the present study are that: 
Knowledge of the previous history of AECOPD hospitalisations and the systemic 
manifestations in COPD can qualify prognostication. 
That clinical approach to treatment of AECOPD has become more aggressive and the 
patients treated more severely ill. 
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GENERAL ASPECTS OF DATA 
MANAGEMENT 
The studies in this thesis are all based on Danish registers. 
The data sources 
Danish registers are unique in that they allow easy, unambiguous linkage at the person 
level. All Danish citizens have a unique personal identifier, a CPR number, assigned 
upon registration in the Civil Registration System and these are only very rarely 
changed. 
For the studies in this thesis, access to data was provided by Statistics Denmark. Data 
were provided in an anonymised version where CPR numbers were encrypted. As 
unlimited data access is not permitted by the Danish authorities, only some variables 
were provided.  The following recapitulation briefly outlines the content of the 
registers relevant for this thesis.    
1.1.1.1 The Civil registration system (CRS) 
The CRS provided information on birth, death and sex. The CRS contains information 
on all persons who are born of a mother already registered in the CRS; have their birth 
or baptism registered in a Danish electronic church register; or reside legally in 
Denmark for 3 months or more. One record is generated per person and it contains 
their date of birth, sex, information on immigration and emigration, and date of death 
128.    
1.1.1.2 The Danish National Patient Registry (DNPR) 
Information on hospital admissions and diagnoses were retrieved from the DNPR. 
This primarily administrative register is the backbone of the management of hospital 
activity in the Danish secondary and tertiary sectors and underlies the reimbursement 
system. A record is generated for each hospital contact with the CPR number of the 
patient. Additional administrative information provided by the DNPR includes 
hospital and department, type of admission, and dates of admission and discharge. A 
record in the DNPR contains at least one diagnosis.The primary diagnosis, which is 
mandatory, is the main reason for the hospital contact. Secondary and supplemental 
diagnoses are also occassionally provided but are not mandatory. The DNPR also 
provides information on procedures. Diagnoses and procedures are chosen from the 
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Health Care Classification System 129. In the period of time relevant to the studies 
included in this thesis, reporting to the DNPR was mandatory for all public or private 
hospitals. 
1.1.1.3 The National Register of Medicinal Product Statistics (NRMPS) 
Information on previous medication was obtained from the National Register of 
Medicinal Product Statistics. The NRMPS contains information on all prescription 
drugs redeemed at Danish community pharmacies. It hinges on the CPR number and 
provides information on dates of redemption, ATC codes, and units of medication 
dispensed. Only prescriptions that were actually redeemed are recorded, and the 
register does not contain information at the patient level on over-the-counter 
medication130. Of note, the medications on which information was retrieved in this 
study cannot be purchased over-the-counter at Danish pharmacies and patients are 
partially reimbursed upon purchase. Arguably, this makes significant unregistered use 
improbable.    
1.1.1.4 The paraclinical dataset 
In contrast to the abovementioned registers, this dataset is not an official register with 
nationwide coverage. Instead, the dataset contains blood sample results from hospital 
laboratories and external laboratories, which have chosen to sign up. Laboratories 
have joined at different points in time and some have only provided results from a 
limited period of time. Each laboratory result is recorded along with the name of the 
test, the CPR number of the patient and the date of sampling. To some extent the 
laboratory where the sample was analysed can be identified. Of note, the laboratories 
report their own name for any given test and the test results mirror the calibration of 
the individual laboratories and can therefore be subject to variation.   
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Definitions used in the studies 
“Admissions” were retrieved from entries in the DNPR, but admissions were merged 
if the date of discharge in one admission equalled the admission date of another.   
“AECOPD admissions” were defined as admissions with either a primary diagnosis 
of COPD (ICD-10: DJ44) or with a combination of either acute respiratory failure 
(ICD-10: DJ96) or pneumonia (ICD-10: DJ13-18) with COPD as a secondary 
diagnosis. Admissions of patients less than 30 years of age were excluded from the 
cohort to minimise inclusion of misclassified asthma. 
“Respiratory admissions” were defined as admissions where the primary diagnosis 
was within the ICD-10 DJ-spectrum.  
“Ventilation” had occurred whenever IMV (BGDA0) and/or NIV (BGDA1) was 
coded during a AECOPD hospitalisation.  
“AECOPD Readmissions” were admissions for AECOPD in patients who had 
previously been admitted for AECOPD. 
COPD EXACERBATIONS – ASSISTED VENTILATION, HAEMOGLOBIN AND PROGNOSIS 
.  
31 
PRESENTATION OF STUDIES 
Three studies (I-III) are included in this thesis. 
1.1. STUDY I 
1.1.1.1 Aim 
To investigate the relationship between the number of previous hospitalisations for 
AECOPD and prognosis in a population of patients with severe AECOPD.  
1.1.1.2 Study subjects 
The cohort of participants in study I were patients who had been treated with assisted 
ventilation for AECOPD for the first time. Patients who had not redeemed medication 
for obstructive airway diseases in the year preceding hospitalisation were excluded. 
Figure 1131 outlines the selection of patients for the cohort. 
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Figure 1 The selection of patients for the study I cohort. 
1.1.1.3 Methods 
To address the association between previous AECOPD admissions and mortality two 
models, for mortality in-hospital (1) and mortality after discharge (2) respectively, 
were fitted. 
Model 1: Sex, time periods, Charlson Comorbidity Indices, mode of ventilation and 
the number of previous hospitalisations as factor variables and age at admission as a 
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continuous variable were fitted into a logistic regression model with in-hospital 
mortality as a binary outcome. Age was included in the model as a continuous 
covariate as the estimates were linear. Interactions between previous hospitalisations, 
and age, sex, and mode of ventilation were tested for by comparisons of likelihood 
but none were significant. 
Model 2: A Cox proportional hazards model was fitted with survival time after 
discharge as the dependent variable and the number of previous hospitalisations as 
independent factor variables along with sex, time periods, and Charlson Comorbidity 
Indices and mode of ventilation. We visually assessed the proportional hazards 
assumption by plotting Schoenfeld residuals. 
1.1.1.4 Results 
There were more than 200,000 admissions for AECOPD from 2003 through 2011 but 
less than 7,000 were eligible for inclusion in the cohort. As can be seen in Figure 2 131 
the majority of patients had had no AECOPD hospitalisations in the year preceding 
the ventilation. 
 
Figure 2 The distribution of the number of admissions in the preceding year for the patients 
included in study I. 
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Mortality in-hospital of the entire cohort was 45%. Eleven percent of patients 
discharged alive died within a month and 39% within a year. Figure 3 131 shows the 
mortality after admission for the entire cohort.   
 
 
Figure 3 Mortality after admission for all patients included in study I. The beginning of the 
abscissa has been manipulated to hold hospitalisations of different lengths. 
The main finding of the study was an increased risk of death both in-hospital and after 
discharge with each additional previous hospitalisation for AECOPD. This 
association was present independently of age, sex, number of comorbidities, mode of 
ventilation and time period. Fejl! Henvisningskilde ikke fundet.Table 1 presents 
adjusted estimates of the odds and hazard ratios with prior hospitalisations, and an 
increasing risk with each prior admission can be discerned. The substitution with 
respiratory admissions for COPD admissions gave a weaker association but in the 
same direction.
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   Number of admissions for AECOPD in the preceding 
year 
 0 1 2 3 
In-hospital death 
Adjusted OR 1 
(ref) 
1.26 [1.11-
1.44] 
1.43 [1.19-
1.72] 
1.56 [1.30-
1.87] 
Death beyond discharge 
Adjusted HR 1 
(ref) 
1.32 [1.19-
1.46] 
1.76 [1.52-
2.02] 
2.10 [1.80-
2.38] 
Table 1 The risk of death before and after discharge respectively, by the number of AECOPD 
hospitalisations in the preceding year. 
Interestingly, IMV was associated with higher risk of death in-hospital (OR 1.71 
[1.53-1.90]) compared to NIV but lower risk after discharge (HR 0.77 [0.71-0.84]). 
A separate analysis was performed, in which all admissions ascribed to respiratory 
causes were substituted for COPD admissions, but this made little difference to the 
associations.  
1.1.1.5 Main conclusions 
Study I demonstrates that the prognosis following ventilation for AECOPD is grim 
and provides evidence that the previously demonstrated link between frequent 
exacerbations and mortality does not just reflect a propensity for severe exacerbations 
among frequent exacerbators.   
1.2. STUDY II 
1.2.1.1 Aim 
To outline the development in the use of assisted ventilation in AECOPD and the 
associated shifts in mortality.  
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1.2.1.2 Study subjects 
The participants in study II were 173,456 AECOPD patients admitted to hospital in 
the time period from 2004 through 2011. Subgroups, which either encompassed all 
patients ventilated during an AECOPD admission or patients ventilated for the first 
time during an AECOPD admission, were established. 
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Figure 4 The selection of patients for study II. 
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1.2.1.3 Methods 
We established the annual number of admissions and ventilations. To explore any 
trends in these numbers, we employed the Kendall τ rank correlation test, which 
identifies monotonic relationships irrespective of non-linearity. We used ANOVA to 
test for trends over time in mean age at first ventilation. 
Temporal changes in in-hospital mortality and mortality and/or readmission within 
one year after discharge were explored with Poisson regressions. Annual numbers of 
admissions were used as the offset and the proportion of patients who died in-hospital 
or died/were readmitted within a year was the dependent variable. Year was added to 
the model as a numerical covariate and the coefficient expressed as odds ratio per 5 
years increases. The model was adjusted for distribution of age, sex and Charlson 
Comorbidity indices. We visually assessed potential non-linearity by adding year as 
a categorical variable, instead of the numercal year, and plotting the year-coefficient 
association.  
1.2.1.4 Results 
The use of assisted ventilation for AECOPD increased in the time period as is depicted 
in Figure 5, panel A. There was very little variation (<10%) in the annual total number 
of AECOPD admissions, which ranged from 20,959 per year to 22,863 per year. 
Assisted ventilation was, in contrast, administered to a larger proportion of patients 
over time.   
The relative use of the different modes of ventilation changed over time, as can be 
seen in Figure 5, panel B. NIV became the dominant mode, and in 2011 more than 
half of IMV treatments were given to patients who also received NIV during the same 
hospitalisation. Nonetheless, the use of IMV did not change. The increase in the use 
of assisted ventilation and the shifting of modes were not solely driven by multiple 
ventilations of the same patients at later hospitalisations as can be seen in Figure 5, 
panel C. 
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Figure 5 The annual number of AECOPD admissions.  
A: All AECOPD admissions.  
B: AECOPD admissions were ventilation was performed.  
C: AECOPD admissions where the patient had not been ventilated for AECOPD before. 
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Development in mortality rates by mode of ventilation can be seen in Figure 6. Panel 
A shows the in-hospital mortality rates among all first-time ventilated patients. The 
time-averaged mortalities among patients receiving the different modes of ventilation 
were different (χ2: p<0.0001). Mortality was lower with NIV than mortality among 
patients treated with both IMV (p<0.0001) and NIV and IMV (p<0.0001) but there 
was no difference between mortality among patients receiving IMV alone and patients 
receiving both IMV and NIV (p=0.99). Panel B shows rates of 1-year mortality among 
first-time ventilated patients discharged alive. The pattern resembled the in-hospital 
mortality in that there was a significant difference overall (p<0.0001) among patients 
receiving NIV and IMV (p<0.0001), and NIV and NIV in combination with IMV 
(p<0001), but no significant difference between patients receiving NIV in 
combination with IMV, and IMV (p=0.09). 
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Figure 6 Development in mortality rates by mode of ventilation over time.  
Panel A: in-hospital mortality rates among all first-time ventilated patients.  
Panel B 1-year morality rates among first-time ventilated patients discharged alive. 
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The adjusted temporal development in mortality can be seen in Table 2. The adjusted 
rate ratios of death in-hospital increased for patients treated with IMV overall. 
Mortality after discharge did not change following either mode. 
 
  NIV IMV All IMV 
Mortality ratios for death per 5 years 
  Unadjusted 1.03 ( 0.92 - 1.15 )  1.18 ( 1.04 - 1.35 )  1.16 ( 1.04 - 1.29 )  
  Adjusted† 0.95 ( 0.85 - 1.07 )  1.12 ( 0.98 - 1.28 )  1.12 ( 1.01 - 1.25 )  
Mortality ratios for death within a year per 5 years§ 
  Unadjusted 1.06 ( 0.95 - 1.18 )  0.91 ( 0.75 - 1.11 )  1.02 ( 0.88 - 1.18 )  
  Adjusted† 1.00 ( 0.90 - 1.11 )  0.85 ( 0.70 - 1.04 )  0.99 ( 0.85 - 1.15 )  
Table 2 Risk of death before discharge and 1 year after discharge for first time ventilated 
AECOPD patients.  
Adjusted for age, sex and Charlson Comorbidity score. 
§: Only patients who survived to discharge 
 
1.2.1.5 Main conclusions 
Study II shows that more patients with AECOPD are being ventilated during 
hospitalisation and that non-invasive ventilation has become the mode most 
frequently used. The use of invasive ventilation has been stable. This, along with an 
increased mortality among patients treated with invasive ventilation at least suggests 
that not only are more patients being offered ventilation but they are also increasingly 
being offered ventilation in spite of severe illness.     
1.3. STUDY III 
1.3.1.1 Aim 
To investigate the distribution of concentrations of haemoglobin in AECOPD patients 
and explore the relationship between concentrations of haemoglobin and mortality.  
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1.3.1.2 Study subjects 
The cohort of participants in study III consisted of 6,969 patients who were admitted 
to hospital for AECOPD for the first time from 2007 through 2012 (Fejl! 
Henvisningskilde ikke fundet.). Only patients admitted to hospitals from which we 
have access to recorded blood test results were included. 
 
Figure 7 The selection of patients for the study III cohort. 
COPD EXACERBATIONS – ASSISTED VENTILATION, HAEMOGLOBIN AND PROGNOSIS 
44 
1.3.1.3 Methods 
For each member of the cohort, we retrieved information on haemoglobin at 
admission, renal function, and selected comorbidities, either through recordings in the 
DNPR or through redeemed prescriptions.  
The WHO definition of anaemia 132 was applied along with a definition of 
polycythaemia proposed by Chambellan et al 126. Based on the first haemoglobin 
measurements made during the hospitalisation patients were divided in three groups: 
anaemia, normal haemoglobin, and polycythaemia.  
To capture the relationship between levels of haemoglobin and mortality after 
discharge we built univariate and multivariate Cox regression models. Different 
models were built for men and women and models were adjusted for renal function 
and comorbidity.  
Subgroup analyses were made firstly among patients who had redeemed medication 
for COPD and secondly among patients who had none of the selected comorbidities 
and renal function in the upper 3 quartiles.  
1.3.1.4 Results 
In our cohort, 30.9 % of the patients had anaemia at admission, but it was more 
common among males, 39.1 %, than among females, 23.8 %. Polycythaemia was 
found in 2.6 % of males and in 13.8 % of females. Baseline characteristics at 
admission and outcomes are presented in Table 3. Mortality was higher both in-
hospital and after discharge among anaemic patients (both p<0.0001).
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Anaemia at 
admission 
Normal 
haemoglobin 
at admission 
Polycythaemia 
at admission 
Total 
  n=2,152 n=4,213 n=604 n=6,969 
Male 1,257 (58.4%) 1,870 (44.4%) 85 (14.1%) 3,212 (46.1%) 
Age/years,median (IQR) 
78.0 (70.0 - 
83.8) 
73.3 (64.0 - 
80.2) 
70.5 (61.9 - 
77.1) 
74.7 (65.4 - 
81.2) 
Medication for obstructive 
airway diseases 
1,468 (68.2%) 3,035 (72.0%) 433 (71.7%) 4,936 (70.8%) 
Antidiabetics 287 (13.3%) 402 (9.5%) 38 (6.3%) 727 (10.4%) 
Antithrombotics 1,218 (56.6%) 1,718 (40.8%) 202 (33.4%) 3,138 (45.0%) 
ACE- and AT2R inhibitors 910 (42.3%) 1,376 (32.7%) 172 (28.5%) 2,458 (35.3%) 
First haemoglobin, median 
(IQR) 
114.4 (106.3 - 
119.2) 
138.6 (132.1 - 
146.6) 
157.9 (154.7 - 
167.6) 
133.7 (120.9 - 
145.0) 
First eGFR 
64.0 (42.0 - 
87.0) 
76.0 (57.0 - 
96.0) 
76.0 (59.0 - 
98.0) 
72.0 (53.0 - 
94.0) 
Died in hospital 249 (11.6%) 217 (5.2%) 42 (7.0%) 508 (7.3%) 
Table 3 Baseline variables and hospital outcome in the study III cohort by haemoglobin 
category. 
Anaemia: Males: haemoglobin<130 g/L, Females: haemoglobin < 120 g/L.  
Polycythaemia: Males: haemoglobin>170 g/L, Females: haemoglobin>150 g/L 
Uni- and multivariate variate analyses of the association between levels of 
haemoglobin and mortality after discharge are presented in Figure 8. The association 
between haemoglobin and mortality was inversely but non-linearly associated with 
haemoglobin below the WHO normal range. 
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Figure 8 Risk of death after discharge for patients discharged alive by concentration of 
haemoglobin. Measurements are rounded to nearest 10 g/L.  
A: Unadjusted  
B: Adjusted for age, use of antidiabetics, use of ACE and/or AT2R-inhibitors, use of 
antithrombotics, quantile of lowest eGFR, cancer, heart failure and AMI.  Only patients with 
measurements of both haemoglobin and eGFR were included. 
1.3.1.5 Main conclusions 
Study III demonstrates that anaemia, in contrast to polycythaemia, is frequent among 
patients admitted to hospital for AECOPD. The study furthermore demonstrates that 
there is an association between levels of haemoglobin and mortality and that mortality 
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is significantly higher among patients with only mild anaemia compared to patients 
with normal haemoglobin.  
DISCUSSION OF METHODOLOGY 
In this chapter the methods used and their appropriateness in all three studies are 
discussed. 
1.3.1.6 The study population 
Due to the unambiguous data linkage in Danish registers it was possible for us to avoid 
inclusion of patients more than once in the cohorts. This is pivotal from a statistical 
perspective, as repeated inclusion of the same subjects in models violates the 
assumption of independence of observations underlying the simpler regression models 
applied here 133.    
Patients who were hospitalised for AECOPD and ventilated for this for the first time 
were included in the study I cohort, provided they had redeemed medication for 
obstructive pulmonary disorders at least once within the preceding year. The decision 
to restrict the study population to only previously medicated patients was taken for 
two reasons: firstly, as we did not have access to measurements of lung function 
impairment prior to the exacerbation, we wanted to narrow the range of impairment 
as much as possible. It has been previously demonstrated that the recognition of 
COPD in a patient is associated with the degree of lung function impairment 113 and, 
arguably, the exclusion of patients who had not been medicated shifted the cohort 
towards patients with severe impairment. The trade-offs are selection which might 
introduce systematic bias and that generalisability is restricted. Secondly, it might be 
argued that the inclusion of patients who, in spite of numerous admissions ascribed to 
COPD exacerbation, had not redeemed any prescriptions, had been misdiagnosed and 
whose misdiagnosis at subsequent admissions had been passed on.  
The analyses in study III were restricted to first-time admitted patients whose 
haemoglobin measured at admission was accessible in our register. Whereas there is 
little reason to suspect bias due to the selection of hospitals, it is reassuring to notice 
that only a very small fraction of patients admitted to relevant hospitals lacked 
haemoglobin measurements, as bias could have been introduced by severely ill 
patients dying before blood samples could be drawn.  
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1.3.1.7 Assessment of exposure and outcome 
In study I, the number of hospitalisations for AECOPD in the year preceding the first 
ventilation for AECOPD was chosen as a proxy for the previous clinical history of the 
patient. Only a fraction of actual AECOPDs leads to hospitalisation and arguably, the 
total number of AECOPDs in the previous year, and not just the AECOPDs that led 
to hospitalisation, would have been a biologically more meaningful variable. It is 
possible to define an indicator of AECOPDs that have been dealt with in the primary 
sector through assessment of prescriptions redeemed by the patient 134, but this 
approach was not chosen here as it has, to our knowledge, not been validated, and as 
the recommendations for handling of AECOPD are in general poorly complied with 
135. 
In study III, the first haemoglobin measurements were used to predict mortality. While 
unambiguous, the first haemoglobin measurement might reflect not only the value at 
admission but rarefication due to fluid infusion given before the sample was drawn 
and concentration due to diuretics. As such the first haemoglobin would not capture 
the true haemoglobin at admission. Though “anaemia”, according to the Oxford 
English Dictionary, literally means “A condition in which there is a deficiency of red 
cells or of haemoglobin in the blood”, this simplistic definition fails to capture the 
complexity of anaemia as a pathological entity. Anaemia has multiple links to 
nutrition, metabolism, inflammation, infection, genetic build-up, organ failure and 
malignancy and the relative importance of these factors differs vastly globally and 
across age groups 136.  While we used measured intervals of haemoglobin 
concentrations in survival models, we described the prevalence of anaemia in our 
population according to the WHO definition. The WHO sets different reference 
ranges for men and women, but does not address the differences known to exist across 
age groups and ethnicity 137. The WHO reference values are easily applied and widely 
used, but their construct validity has been contested in light of this heterogeneity 138. 
We compared our prevalence estimates to estimates found in the literature only after 
a standardisation to the WHO anaemia definition and the distribution across the sexes 
in our population, but - aware of disagreement on this point – we should have liked to 
standardise distributions of age and ethnicity as well. It is possible that divergent 
estimates reflect these baseline demographics rather than biologically and clinically 
relevant differences across populations.  
1.3.1.8 Temporal changes 
Absolute numbers of treatments might be of some interest from a organisational 
perspective but in order to understand clinical practice, relative numbers are needed. 
In other words, what is the likelihood of being having a treatment given a set of 
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baseline characteristics at different points in time? As these baseline characteristics 
are not routinely recorded, any answer to this relies on the rather strong assumptions 
of both unchanging incidence and unchanging baseline characteristics, and these 
assumptions allow employment of absolute numbers as a proxy for likelihood. These 
assumptions are, however, challenged by previous Danish studies, one of which found 
that the incidence of hospitalisations decreased in spite of a constant prevalence of 
COPD that had at some point required hospitalisation in the period from 2002-2009 
139. Another study found that the use of intensive care, the burden of comorbidity, all-
cause previous hospital admissions, and mortality increased, thereby prompting 
suggestions that the severity of disease among patients hospitalised for COPD was 
increasing 140. 
1.3.1.9 Statistical modelling 
The DNPR does not permit reconstruction of the time sequence of treatments initiated 
during hospitalisation. Therefore, in study I and II it is not possible to establish the 
date at which ventilation was initiated. When in-hospital mortality is assessed as a 
binary outcome, the need to establish the exact day of entry into the cohort is 
circumvented. However, what cannot be dealt with so easily is the immortal time bias 
that might have been introduced by different time to initiation of ventilation across 
exposure groups (i.e. groups with different numbers of previous hospitalisations). 
Immortal time bias is “created when there exists a period of time during which the 
outcome of interest […] for one of the cohorts cannot possibly occur” 141 and can 
severely affect the validity of estimates in survival analysis142. If, for instance, 
ventilation happens to be initiated at the admission day among patients in study I who 
have had many AECOPD hospitalisations (e.g. because COPD is recognised 
immediately) and not till day 2 in patients who have not been hospitalised for 
AECOPD before (e.g. because it takes time to recognise the condition), the latter 
group will have been “statistically immortal” for two days. The association between 
previous hospitalisations and death would therefore tend to be exaggerated.  
1.3.1.10 Misclassification 
Misclassification is erroneous assignment of either exposure, covariates, or outcome 
to study records. It can be either non-differential (i.e. the probability of erroneous 
assignment is the same for all records) or differential (i.e. the probability of erroneous 
assignment is higher in subsets of records) and both kinds may lead to bias.  
Diagnosis of AECOPD 
To isolate hospitalisations for AECOPD in all 3 studies, we followed the definition 
described by Thomsen et al. 143 where “COPD-hospitalisations” were hospitalisations 
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of patients of at least 30 years of age with either a primary diagnosis of COPD (ICD-
10: DJ44) or with a combination of either acute respiratory failure (ICD-10: DJ96) or 
pneumonia (ICD-10: DJ13-18) as the primary diagnosis and COPD as a secondary. 
The positive predictive value for COPD of this definition was 92%, but 19% of 
patients coded for either pneumonia or respiratory failure but not COPD had 
underlying COPD. The negative predictive value is unknown.    
The definition of COPD exacerbations relies on the clinical presentation of the patient 
1 and clinical recognition of underlying COPD in a patient in respiratory distress 
depends on either a previous diagnosis of COPD or a clinical history suggestive of 
COPD, as lung function impairment cannot be assessed during exacerbations. COPD 
is underdiagnosed 38 in the general population as well as in patients admitted to 
hospital for respiratory complaints 110. Furthermore, it is only mandatory to enter one 
diagnosis per patient record to the Danish National Patient Registry.  
Most, but not all, exacerbations are precipitated or complicated by infection 144 and 
there is no sharp demarcation between exacerbations and pneumonia in COPD, 
though the aetiology and outcomes are different 116. Also, the extent to which COPD 
patients hospitalised for reasons other than exacerbation are filed in the register with 
a primary diagnosis of COPD is unknown but it is known that it can be clinically 
challenging to distinguish exacerbations from day-to-day decline in end-stage COPD. 
In summary, it is possible, that many true exacerbations of COPD are missed while 
admissions of COPD patients for reasons other than exacerbations/pneumonia are 
erroneously included, when the abovementioned definition is applied.   
The inclusion of patient records where COPD exacerbation was not the real reason 
for admission and the exclusion of true COPD exacerbations limit the validity of the 
study.  
The probability of a COPD diagnosis being assigned, given COPD in the subject in 
question, may depend on the severity of lung function impairment and acute 
derangement. In study I, from a validity perspective, this is problematic as it 
potentially contributes to differential misclassification. In an effort to circumvent bias 
introduced by misclassification of prior COPD admissions, a separate analysis was 
performed, in which all admissions ascribed to respiratory causes were substituted for 
COPD admissions. There was an association with mortality that resembled the 
association with COPD admissions, which argues against a large impact of 
misclassification.  
As previously mentioned, we differentiated in study I between first time ventilations, 
which were preceded by filled prescriptions for drugs used in obstructive airway 
disease, and first time ventilations, which were not. In fact, among patients who had 
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not redeemed any prescriptions for COPD medication in the preceding year, an 
increasing number of previous COPD-admissions was associated with a decreased 
risk of death in-hospital. In itself, this serves as a reminder of the dangers inferred by 
an assumption of a direct correspondence between register and reality. A possible 
explanation for this biologically absurd finding is that a patient by not having any 
COPD medication prescribed or redeemed after an admission for COPD is selected or 
selects himself as a patient whose prognosis is particularly good, probably because 
the diagnosis of COPD is wrong or the disease is in an early stage. 
Diagnoses of comorbidities 
The Charlson Comorbidity Index (CCI) was originally developed for prognostication 
of 1-year survival from medical chart review in medical patients 145. The index 
encompasses a number of comorbidities and points are assigned for each comorbidity 
proportionally to the association between that comorbidity and mortality. In some 
adaptations, points are assigned for advancing age. The index has been extensively 
modified to be calculated from medical registers and validated in different populations 
146. The application of the Charlson Index in register-based studies has the advantages 
of producing one integrated parameter from a lot of different diseases, of being easy 
to calculate and - at a glance – being easy to interpret. There are, nonetheless, 
noteworthy problems.  
Firstly, a register-based calculation of CCI has not been directly validated in a 
population of patients with exacerbations of COPD. Therefore, the assignment of a 
given number of points to different diseases, originally meant to reflect the prognostic 
impact of these diseases might weigh too heavily or too lightly in a population of 
present day AECOPD patients. To our knowledge, only a Canadian study has made a 
direct attempt to validate CCI in COPD patients 147. The study demonstrated that CCIs 
based solely on hospital admission registers had an acceptable precision for predicting 
1-year mortality among incident and prevalent COPD cases, but the frequencies and 
impacts of different comorbidities might be different in a population admitted to 
hospital for exacerbations, as this population might differ from COPD patients in 
stable phase.   
The Danish National Patient Registry consists of entries of the diagnoses that were 
the main reasons for admissions or out-patient visits and in some cases a secondary or 
supplementary diagnosis 129. As such, the validity of the registration is highly 
dependent on the disease in question. The positive predictive values of diagnoses in 
the DNPR are in general high 148, but little is known about the negative predictive 
values. In simple cases with non-differential misclassification of a confounder 
variable, underreporting results in residual confounding and estimates of the effect of 
the primary variable inbetween the unadjusted and the fully adjusted values, but the 
implications in study I and study II might be more complex. Firstly, there is probably 
an association between the number of admissions and the chance that any comorbidity 
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present has been registered, leading to non-differential misclassification in study 1. 
Secondly, Charlson Comorbidity Indices are incorporated in our regression models as 
a categorical (in this case, three-level) variable and as such, might introduce non-
differential misclassification 149.   
Code-drifting A potential problem in relation to the coding system in Danish registers 
that is not well described is the consistency of coding practice over time. We know 
from American studies that clinical recording can change rapidly in response to 
changes other than shifts in the actual incidence of a disease entity 150. The DNPR is 
mainly set up for administrative purposes and measures of activity at individual 
hospital units are derived from it. Reimbursement might differ severalfold with 
different but arguably accurate diagnostic codes and a drift towards more “expensive” 
codes is likely to have taken place. In the American study the code drifting had 
profound consequences for the estimates of mortality in consecutive years which 
might lead to erroneous conclusions. Our inclusion of patients is based on diagnostic 
codes and it is reassuring that the number of admissions to hospital for AECOPD in 
study II was nearly constant across the study period. We cannot, however, rule out 
that a drift in case mix between subgroups biases our results.     
1.3.1.11 Confounding 
“Confounders are factors (exposures, interventions, treatments, etc.) that explain or 
produce all or part of the difference between the measure of association and the 
measure of effect that would be obtained with a contrafactual ideal” 149. A serious 
limitation, that in fact pertains to all studies, is the lack of assessment of physiological 
status which might constitute such a confounder. The Danish registers contain only 
sporadic information on stable phase lung function and acute deterioration. The 
inclusion in study I of only patients in need of assisted ventilation only partly 
eliminates this source of unmeasured confounding. Physiological assessments are 
under certain circumstances reported in patients seen in out-patient clinics, as part of 
a quality surveillance, and these data were retrieved. Upon examination, it became 
evident that these data, while they enabled an adjustment for FEV1 in a small 
subgroup of patients, were prone to confer confounding by indication. Therefore, it 
was decided not to adjust for FEV1.  
Whether to consider a coexisting condition a comorbidity in its own right or a 
component in COPD has an impact on how to address its presence in survival models. 
Considering a comorbidity an independent coexisting condition allows direct 
adjustment. In contrast, a comorbidity that reflects the severity of COPD cannot be 
directly adjusted for, as this would lead to bias 149. As an example, COPD patients 
more frequently have cardiovascular disease compared to patients without COPD 22. 
This might just reflect a shared risk factor, smoking, but there is also evidence for an 
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association that is independent of smoking 151. By adjusting for CCI, which includes 
previous AMI, we might unintentionally have partly adjusted for the severity of 
COPD. The same considerations apply to the association between concentrations of 
haemoglobin and COPD in study III.  
Estimates of prevalence are relevant only if the selection of the population that gave 
rise to the estimate is clearly described and if this population forms a logical and 
operational entity. Our population was all first-time admitted AECOPD patients, 
whose selection is relevant from an organisational-clinical perspective as intervention 
could potentially be instigated at this point, and from a research point of view as 
haemoglobin is not – to our knowledge – associated with acceleration of the first 
hospital admission.  Our prevalence should not be interpreted as describing the 
prevalence in the COPD population as a whole, as there might be huge differences 
between the prevalence in patients with and without exacerbations and at different 
points along the COPD trajectory. 
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DISCUSSION OF RESULTS 
1.3.2. STUDY I  
The prognostic role of the clinical history has been assessed in many studies 
43,46,47,134,152–169. Previous exacerbations are known to predict mortality in AECOPD, 
but to our knowledge we are the first to address the association in a population of 
patients with uniformly severe AECOPD.  
From what was known when we commenced our study, it could not be inferred 
whether the association between hospitalisations and mortality just reflects a 
propensity among frequent exacerbators for development of severe exacerbations with 
an inherent high fatality rate. Alternatively, the association is completely or partly 
independent of AECOPD severity. The association found between the number of 
previous associations and mortality in our study lends support to the latter.  
We can only speculate about the pathological linking of previous exacerbations and 
mortality. The association might reflect that the underlying lung function impairment 
is more severe among frequent exacerbators or that the frequent exacerbators have to 
a larger extent not yet recovered from the latest exacerbation, a process which might 
take months 170 or might never be completed 171. Alternatively, the frequent 
exacerbators in our study might be frequent exacerbators because of pre-ventilation 
frailty, whose frailty has lowered the threshold for hospital admittance in the year 
prior to the ventilation. It is also possible that frequent and rare exacerbators 
experience exacerbations with fundamentally different underlying pathology. 
Differences in the presence and nature of microbiological agents across frequent and 
non-frequent exacerbators have been demonstrated 172 and furthermore, as there is 
evidence that particular infectious agents - present at initiation of NIV - predict NIV 
failure 173, such aetiological differences might contribute to the linking of frequent 
exacerbations and mortality. 
Clinical impact 
It is of paramount importance to stress that inferences cannot be drawn from this study 
about the futility of either assisted ventilation or repeated ventilation. Firstly, the 
population studied was treated with assisted ventilation for the first time and is 
therefore neither generalisable to all COPD patients nor to COPD patients treated with 
repeated ventilation. Secondly, by design this study did not aim to make predictions, 
meeting this aim would have required another statistical set-up and validation in a 
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separate cohort. Thirdly, the difference between significant odds ratios and clinical 
impact should be appreciated.   
1.3.3. STUDY II   
A number of studies address the use of different modes of ventilation in COPD 
63,86,87,174–182. The surge in the use of NIV in our study mirrors the general international 
trend 86,175,178,179, although the use of NIV in Denmark commenced rather late. It is 
interesting that IMV has not lost foothold with the introduction of NIV, as NIV has 
been branded the most efficient treatment of choice for AECOPD and as declining 
use has been observed almost all other studies. The mortality rates found in the Danish 
population are in accordance with the rates seen in a recent European survey183, but 
are somewhat higher than the rates found in the study by Chandra et al 86, which might 
be explained by case mix (e.g. higher admission rates, different discharge practice) in 
the US.  Being a series of snapshots of clinical practice, study II does not allow firm 
conclusions regarding the shifts in treatment seen in our population but several 
hypotheses can be outlined to explain the increasing in-hospital mortality in the IMV-
groups, which at a glance seems worrying. It must, however, be interpreted in the 
context of the changing practice. Figure 9 maps out some explanations for the 
increasing mortality over time in the IMV overall group. 
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Figure 9 Possible explanations for the increasing IMV in-hospital mortality over time. 
Clinical impact 
Surveys published at the time of our setting up study II86,175  led us to assume that the 
use of IMV in Denmark would have declined in parallel with the increasing use of 
NIV. Any such decline however, was not observed. It might be that throughout the 
studied period of time IMV has been administered to those patients whose condition 
would at any time warrant the treatment. Alternatively, the introduction of NIV has 
freed ICU resources to be allocated to patients whose grim prognosis would formerly 
have led to their not being prioritised. If indeed more patients with high acute and 
chronic severity are offered a trial of IMV, future studies will have to clarify if this 
meaningfully prolongs life or extends the dying process.   
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1.3.4. STUDY III 
A number of papers have examined anaemia in COPD 79,123,125–127,184–196. In our study 
we did find a high prevalence of mainly mild anaemia, whereas grave anaemia and 
polycythaemia were rare.  The prevalence spectrum reported in the literature is broad, 
ranging from less than 5% to more than 40%. The prevalence of 30.9 % in our 
populaltion is thus in accordance with previous studies. Apart from an American study 
that relied on diagnostic codes rather than actual haemoglobin measurements 127, ours 
is, to our knowledge, the largest study of anaemia prevalence in COPD so far and one 
of few concerned with anaemia in acute exacerbations. Importantly, our population is 
not selected based on absence of certain comorbidities, an exclusion which can 
explain the lower prevalence found in some papers 185. Comorbidities might, 
paradoxically, also explain a higher prevalence found in a populations where diabetes 
123 is common.  
Selection of patients based on severity of acute illness might also shift the prevalence 
of anaemia. In a study where only patients receiving NIV were included 191, anaemia 
was more frequent than in our population but, in contrast, the prevalence was low 
among invasively ventilated patients 79. The relation between severity of acute illness 
is very likely confounded by age and severity of stable phase COPD.  
In our population, the lower the concentration of haemoglobin the higher the mortality 
after discharge. Though we are not aware of any large, directly comparable studies, a 
similar relation is seen among  stable phase COPD patients 126.  
Even mild anaemia was significantly associated with mortality in our study. In a sense, 
this mirrors a study of  stage III/IV COPD patients, which also found that levels well 
above the lower normal range were associated with lower risk 194.  
Clinical impact 
The relationship between anaemia and mortality in our study strikingly resembles the 
pattern found in a large population of patients with heart failure 197, in as much as even 
mild anaemia associates with increased mortality, and mortality is lower the higher 
the haemoglobin concentration. One might even speculate that anemia is a general 
measure of morbidity in chronic disease? Should we completely rethink the concept 
of normal ranges in patients with chronic disease? The cautious but evasive answer to 
this is that we might have to be careful when we use normal ranges. We do not yet 
have evidence that targeted treatment of mild anaemia improves prognosis per se, but 
the results of study III imply that anaemic AECOPD patients constitute a high risk 
subpopulation who might benefit by close clinical surveillance and support.  
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PERSPECTIVES 
At the end of the day, what is primarily important in the field of risk factor assessment 
is the identification of “red alerts” which should trigger some clinical action. Per se, 
observational studies will never answer questions of causality and will therefore not 
allow us to conclude that exacerbations should be prevented, that assisted ventilation 
should be used in a larger part of the population or that anaemia should be medically 
treated.  
Though Hurst et al. did not find any correlation between haemoglobin and 
exacerbation frequency (possibly because haemoglobin was entered into the study as 
a linear predictor which might obliterate any correlation if the true association is U-
shaped) 42, correlations have been found between haemoglobin and inflammatory 
markers respectively, and frequency of exacerbations 19,126,198. It is an intriguing 
thought that the associations between previous exacerbations, haemoglobin, and 
numerous inflammatory markers respectively, and mortality might reflect aspects of 
the same pathological process whether this be systemic inflammation or another 
overarching “systemic component”. In many studies, relative mortality significantly 
increased, but, to our knowledge, so far no predictor has explained a large absolute 
proportion of the variability in clinical courses. It might be that the impact of such a 
“systemic component” is limited, or, as mentioned, that hitherto applied proxies do 
not reflect the true exposure accurately. Another possible explanation is that all-cause 
mortality is too broad an outcome. To address the latter, an interesting future study 
would be to explore the associations between different types of anaemia or previous 
exacerbations and future events related to COPD progression (installation of 
domiciliary oxygen etc.).   
The biological relevance of mapping the changing pattern of clinical actions and 
decisions lies primarily in the impact that such changes, if unrecognised, can have on 
conclusions drawn from studies of population incidence and risk factors. A thorough 
description of and adjustment for case mix is paramount to any epidemiological or 
clinical study and it is a fair critique of study II that that is exactly what we do not 
provide for our analysis of mortality over time, as we do not address changes in 
severity. Other studies have addressed the case mix, but most often the trade-off is a 
necessity to restrict data collection to critical care units199, thereby the dissemination 
of treatments to wards is missed. What our study does uniquely provide is an estimate 
of the usage of assisted ventilation for AECOPD irrespective of where the treatment 
is administered and a suggestion that the price paid for multiplying the use of 
ventilation has not been an increased mortality. When results of not only venous but 
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also arterial blood tests become accessible, it will be possible to trace changes in case 
mix and its impact on mortality. 
The organisational relevance of our study lies in our showing that, although NIV has 
gained a strong foothold in the treatment of AECOPD, there is, as the number of 
treatments has not declined, still a perception of benefit derived from IMV among 
Danish clinicians. We do not, however, know if this perception differs markedly 
among clinicians or among hospitals or if the treatment administered to a given COPD 
patient has changed or depends on factors not directly related to the clinical condition. 
In collaboration with British researchers I have set up a study of the between hospitals 
variation in the use of IMV. Setting the study in Great Britain allows us to adjust for 
case-mix and we aim to uncover if the propensity of some hospitals to use IMV 
markedly diverges from the national average.    
Our observations indicate that haemoglobin levels below the reference range are grim 
prognostic markers, but we cannot ascertain whether low haemoglobin in itself 
negatively influences the clinical course, it merely correlates with a detrimental 
development as an innocent bystander or indeed is a beneficial compensatory 
mechanism without which the organism would be even worse off, though the latter is 
biologically unlikely. While intervention studies are ultimately required, 
observational studies gain their merit by generating hypotheses, by alerting 
researchers to potential harms, and by describing the make-up of the population that 
an intenvention should be targeted at. Our results are therefore relevant should a 
randomised trial of the impact of some intervention in AECOPD patients with 
anaemia be set up. Estimates of prevalence are relevant in power calculations, as is 
the strength of correlation between levels of haemoglobin and mortality for 
identification of a target population. Further prerequisites for deciding on a rational 
intervention in a trial would, however, be a thorough description of the frequency of 
different types of anaemia and how they respectively correlate with mortality. Our 
data did, as stated, unfortunately not allow us to explore this issue but a future study 
could be set up potentially involving a biobank to ensure that the collection of 
haematological parameters was not biased by sampling-by-indication. 
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CONCLUSION 
In conclusion, the studies presented in this thesis support that both the previous history 
of exacerbations and the haemoglobin at admission are risk factors for mortality 
among AECOPD patients. Also, the introduction of non-invasive ventilation has 
evoked a profound change in the treatment of severe AECOPD, where more patients 
are treated with assisted ventilation without large changes in mortality among 
ventilated patients. 
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Appendix 
Literature searches 
Study 1 
The search strategy was to identify studies where the association between previous 
exacerbations and mortality following exacerbations were examined. 
Pubmed was, as per June 14, 2016, searched for: 
(((((((((((((((((((((((("previous admission") OR "previous admissions") OR "previous 
hospital admission") OR "previous hospital admissions") OR "frequency of 
exacerbation") OR "frequent exacerbation") OR "frequent exacerbations") OR 
"frequent aecopd")) OR subsequent severe exacerbation*[tiab]) OR subsequent 
exacerbation*[tiab]) OR second exacerbation*[tiab]) OR second severe 
exacerbation*[tiab])) OR frequency of severe exacerbation*[tiab]) OR exacerbation 
frequency[tiab])) OR exacerbation incidence*[tiab])) AND (((((("Pulmonary Disease, 
Chronic Obstructive"[Mesh]) OR ((("chronic obstructive lung"[Title/Abstract]) OR 
"Chronic Obstructive Pulmonary"[Title/Abstract]) OR copd[Title/Abstract]))))))) 
AND ((Danish[lang] OR English[lang] OR Norwegian[lang] OR Swedish[lang])))) 
AND ("Mortality" OR "Death" OR "fatality" OR "fatal")))  
This search yielded 198 papers. 
An additional search in Embase at the time the study was conducted had retrieved 489 
papers. 
A primary sorting by title and abstract was conducted and doublets were removed.  
A secondary sorting was conducted based on the entire text. Reference lists in key 
papers were searched and 21 relevant papers were retrieved in total.  
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Study II 
Pubmed was, as per June 16, 2016, searched for: 
((((trend[tw] OR trends[tw])) OR "trends"[Subheading])) AND (((((((assisted 
ventilation*[tw]) OR Mechanical Ventilation*[tw]) OR "Respiration, 
Artificial"[Mesh]) OR Non invasive Ventilation*[tw]) OR Noninvasive 
Ventilation*[tw])) AND (((((("Pulmonary Disease, Chronic Obstructive"[Mesh]) OR 
"chronic obstructive lung"[tw]) OR "Chronic Obstructive Pulmonary"[tw]) OR 
copd[tw]) OR Chronic Obstructive Airway[tw]) OR Chronic Airflow 
Obstruction*[tw])) 
The search yielded 148 hits 
An additional search in Embase at the time the study was planned yielded 157 papers.  
A primary sorting by title and abstract was conducted and doublets were removed. 
A secondary sorting was conducted based on the entire text. Papers concerned with 
the use of ventilation for patients with acute COPD - or from which information 
regarding subgroups with COPD could be extracted - were considered.  
Referencelists in key papers were searched and 12 relevant papers were retrieved in 
total. 
Study III 
A Pubmed/Embase search was undertaken to identify studies in which the association 
between concentrations of haemoglobin (which could also be expressed as 
haematocrit) and mortality was assessed. 
Pubmed was, as per June 14, 2016, searched for: 
(((((((((((("Pulmonary Disease, Chronic Obstructive"[Mesh]) OR ((("chronic 
obstructive lung"[tw]) OR "Chronic Obstructive Pulmonary"[tw]) OR 
copd[tw])))))))) OR Chronic Obstructive Airway[tw]) OR Chronic Airflow 
Obstruction*[tw])) AND (((((("Mortality"[Mesh]) OR Mortalit*[tw]) OR 
"mortality"[Subheading]) OR "Death"[Mesh]) OR Death*[tw]) OR Survival[tw])) 
AND (((((((((("Anemia"[Mesh]) OR Anemia*[tw]) OR "Hemoglobins"[Mesh]) OR 
Hemoglobin*[tw]) OR Haemoglobin*[tw]) OR Anaemia*[tw]) OR haematocrit[tw]) 
OR hematocrit[tw]) OR hgb[tw]) OR polycyt*[tw]) 
This search yielded 311 papers. 
An additional search in Embase was conducted at the time of the study. 
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A primary sorting by title and abstract was conducted and doublets were removed.  
A secondary sorting was based on the entire text, and identified studies concerned 
with anaemia and mortality and/or serious adverse events from which estimates of 
risk could be inferred. The reference lists of key papers were likewise searched and 
yielded 18 papers in total. 
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